Author name: Leonardo Arias

BioSpace did a deep dive into biopharma female executives who navigated difficult markets to lead their companies to high-value exits.

Scott Gottlieb, who served as FDA commissioner during the first Trump administration, wrote in a JAMA editorial that China is speeding drugs to market and could potentially surpass the U.S. in the innovation game.

AMX0035—approved as Relyvrio in 2022 for amyotrophic lateral sclerosis but voluntarily pulled from the market last year— was unable to distinguish itself from placebo in a mid-to-late-stage trial of progressive supranuclear palsy.

In a new report from Medscape, physicians say a lack of qualified applicants is hampering efforts to fill open positions. Many worry the situation could get worse over the next decade.

Mike Stuart has been the California Blues giant’s interim CEO since March. Now, he’s officially stepping into the role.

Improving health data exchange is a worthy goal, but the initiative has to overcome challenges like data security, under-resourced providers and slow technology uptake, experts say.

Marte es hoy un planeta extremadamente árido, cuyas condiciones de presión y temperatura impiden que el agua líquida exista en su superficie. Sin embargo, muchos indicios geológicos y mineralógicos apuntan a que, en un pasado remoto, el Planeta Rojo albergó …

Novartis has bet up to $772 million to gain access to BioArctic’s BrainTransporter platform, which was leveraged in a partnership with Eisai to produce Leqembi.

Regeneron’s cemdisiran, used alone or in combination with its complement inhibitor Veopoz, significantly improved activities of daily living in patients with generalized myasthenia gravis.  

A medida que las bacterias se vuelven cada vez más resistentes a los antibióticos y otros fármacos antibacterianos, aumenta la necesidad de encontrar alternativas a tales medicamentos.   En un nuevo estudio, se han identificado sustancias antimicrobianas aún no uti …